杨宁介入医学网

Two different percutaneous arterial access approaches have been used for HAIC: the first approach entails the use of implantable port-catheter systems, and the second approach involves repeated hepatic artery catheterization. 两种不同的经...

A standard chemotherapy regimen for HAIC has yet to be established, increasing the challenge of interpreting trial results. HAIC的标准化疗方案尚未建立，这增加了解释试验结果的挑战。 Cisplatin and 5-FU were the most commonly used chemotherap...

Studies on HAIC have included populations with various degrees of intrahepatic tumor burden, including the possible presence of PVT/EHS. 对HAIC的研究包括了不同程度肝内肿瘤负荷的人群，包括可能存在PVT/EHS。 Studies on patients with PVT who r...

Immune checkpoint inhibitorbased combinations have changed the treatment paradigm for advanced HCC [59,60] and are likely to remain the cornerstone of systemic treatment in the next few years. 基于免疫检查点抑制剂的联合治疗已经改变了晚期HC...

HAIC combined with radiation therapy (RT) has also been extensively investigated, particularly in subgroups of patients with PVT. HAIC联合放疗(RT)也已被广泛研究，特别是在PVT患者的亚组中。 Han et al. [ 51 ] conducted a small-scale single-ar...

HAIC has been combined with sorafenib to leverage the synergistic effects of the combination. HAIC已与索拉非尼联合使用，以利用该联合使用的协同效应。 A randomized Phase 2 trial was conducted to compare HAIC plus sorafenib with sorafenib alo...

Subcutaneous or intramuscular interferon-alpha (IFN-) has been used in combination with intravenous chemotherapy for advanced HCC to enhance antitumor activity [55]. 皮下或肌内干扰素(IFN-)已与静脉化疗联合用于晚期HCC，以增强抗肿瘤活性[ 55 ]...

肝癌是全世界范围内常见的消化系统恶性肿瘤，我国肝癌的发病率和死亡率在恶性肿瘤中分别排列第4位和第2位。肝癌具有早诊困难、进展迅速，预后较差等特征， 特别是对于中晚期肝癌患者的治疗选择非常有限。 一项2期临床试验评估了钇90微球疗法联合免疫药物Opdiv...

超声显示高回声区域替代原先的病变。但是这一特征并不可靠。 The US shows hyperechoic area replacing the original lesion. This feature, however is unreliable for assessing the outcome of treatment....

栓塞后综合征（post embolization syndrom，PES）是指肝动脉栓塞后出现的右上腹疼痛，发热，疲劳，恶心呕吐。其实所谓栓塞后综合征的定义并不十分明确，包括发热超过38c吗？疼痛是指需要止疼药超过一周吗？... 定义不统一，报道的发生率差异性较大。 但栓塞...